At Alteris Therapeutics, they firmly believe that alternative splice forms hold the key to designing truly disease specific drugs. Alternative splicing is a normal process that involves from 30-60% of all genes in the human body.

But an exciting and key feature is that many “splice variants” occur that are specific to diseases. Thus, these splice variants represent disease-specific proteins. They believe that the identification of novel splice forms and their expression patterns will be a significant area of discovery in the immediate future, much as the fields of genomics and proteomics have already harvested new targets. Akin to these disciplines, they term this new field spliceomics. But because it can quickly identify relevant targets and then zero in on critical regions in a protein, spliceomics is the potential of genomics and proteomics realized.

Contact Information

416 South 10th Street
Philadelphia, PA 19147
United States

Overview

Total FundingEmployeesLast Funding DateStatus
unknown2003-07-02Acquired

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2003-07-02SeedBioAdvance